Trials / Completed
CompletedNCT00606281
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group-Comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 258 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this trial is to evaluate the clinical efficacy and safety of aripiprazole in comparison to placebo in patients with Bipolar I Disorder experiencing a manic or mixed episode.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aripiprazole | oral, 24mg/day |
| DRUG | placebo | oral, 0mg(4tablets)/day |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2010-11-01
- Completion
- 2010-11-01
- First posted
- 2008-02-01
- Last updated
- 2014-02-12
- Results posted
- 2014-02-12
Locations
12 sites across 4 countries: China, Japan, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT00606281. Inclusion in this directory is not an endorsement.